The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Urology

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.juro.2008.01.145PMID 18423697PMCID PMC2684818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men

  2007cited by this paper
• The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.

  2007cited by this paper
• Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

  2006cited by this paper
• Assessment of male sexual function by the Brief Sexual Function Inventory

  2006cited by this paper
• Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results.

  2006cited by this paper
• Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

  2004cited by this paper
• Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

  2004cited by this paper
• Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

  2004cited by this paper
• The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

  2002cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

  2002cited by this paper
• The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.

  2002cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

  1998cited by this paper
• The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

  1998cited by this paper
• The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients.

  1996cited by this paper
• Steroid 5 alpha-reductase: two genes/two enzymes.

  1994cited by this paper
• Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

  1993cited by this paper
• Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

  1992cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia.

  1992cited by this paper
• Testosterone Deficiency As a Risk Factor for Hip Fractures in Men: A Case‐Control Study

  1992cited by this paper
• Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.

  1990cited by this paper
• The source of plasma dihydrotestosterone in man.

  1971cited by this paper

• Structural determinants of oxygenated benzalkonium-like disinfectants as human and rat 5α-reductase 1 inhibitors: Integrated SPR binding analysis with docking.

  2026cites this paper
• Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer

  2025cites this paper
• Chalcone analog-based 5-reductase 1 inhibition in neurosteroidogenesis: Mechanistic insights from integrated SPR binding, enzyme kinetics, 3D-QSAR, and docking.

  2025cites this paper
• Evaluation of the Effect of Finasteride and Tamsulosin on Glucose, Lipid, and Oxidative Stress Factors of Patients with Benign Prostatic Hyperplasia

  2025cites this paper
• Does Propecia Cause More Harms than Good: Assessing Reproductive and Non-Reproductive Effects of Finasteride on Male Health

  2024cites this paper
• Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?

  2024cites this paper
• Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines

  2024cites this paper
• Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders

  2023cites this paper
• Anabolic–androgenic steroids: How do they work and what are the risks?

  2022cites this paper
• The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies.

  2021cites this paper
• Androgens’ Effects across the Lifespan in Men and Animal Models

  2021cites this paper
• A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen.

  2021cites this paper
• Osteoporosis in men: what is similar and what is different?

  2021cites this paper
• Post-finasteride syndrome: a surmountable challenge for clinicians.

  2020cites this paper
• Diet-derived fruit and vegetable metabolites show sex-specific inverse relationships to osteoporosis status.

  2020cites this paper
• The physiology of male reproduction: Impact of drugs and their abuse on male fertility

  2020cites this paper
• Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates.

  2020cites this paper
• Diet-derived fruit and vegetable metabolites suggest sex-specific mechanisms conferring protection against osteoporosis in humans

  2019cites this paper
• Aging and the Male Reproductive System.

  2019cites this paper
• Role of androgens in cardiovascular pathology

  2018cites this paper
• Simultaneous determination of dihydrotestosterone and its metabolites in mouse sera by LC-MS/MS with chemical derivatization.

  2018cites this paper
• A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride

  2018cites this paper
• Computational analysis of genomic variants affecting predicted microRNA:target interactions in prostate cancer.

  2018cites this paper
• Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment

  2018cites this paper
• Gonadal Function and Bone Mineral Density in Young Male Cancer Survivors

  2018cites this paper
• The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption

  2018cites this paper
• Medical management of benign prostatic hyperplasia

  2018cites this paper
• Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

  2017cites this paper
• Is Dihydrotestosterone a Classic Hormone?

  2017cites this paper
• Effect of oral administration of Tribulus terrestris extract on semen quality and body fat index of infertile men

  2017cites this paper
• Testosterone Plus Finasteride Prevents Bone Loss without Prostate Growth in a Rodent Spinal Cord Injury Model

  2017cites this paper
• Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction

  2017cites this paper
• Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels

  2017influential citation
• Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.

  2017cites this paper
• [Finasteride adverse effects: An update].

  2016cites this paper
• Re: A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia.

  2016cites this paper
• Androgen actions on endothelium functions and cardiovascular diseases

  2016cites this paper
• Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study

  2016cites this paper
• 5-Alpha-Reductase Inhibitors and Combination Therapy.

  2016cites this paper
• Physiology of the Hypothalamic Pituitary Gonadal Axis in the Male.

  2016cites this paper
• Pituitary Gonadal Axis in the Male

  2016cites this paper
• Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study

  2015cites this paper
• Testosterone and Adult Male Bone: Actions Independent of 5&agr;-Reductase and Aromatase

  2015cites this paper
• Rôles et mécanismes d'action du récepteur nucléaire COUP-TFII dans la régulation de l'expression des gènes Star et InsI3 dans les cellules de Leydig

  2015cites this paper
• 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia

  2015cites this paper
• Penile Rehabilitation Strategies Among Prostate Cancer Survivors.

  2015cites this paper
• Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia

  2015cites this paper
• A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia

  2015cites this paper
• Sex steroid actions in male bone.

  2014cites this paper
• Androgens and estrogens in skeletal sexual dimorphism

  2014cites this paper
• Erectile Dysfunction and Infertility

  2014cites this paper
• Differential associations of testosterone, dihydrotestosterone and oestradiol with physical, metabolic and health‐related factors in community‐dwelling men aged 17–97 years from the Busselton Health Survey

  2014cites this paper
• In Search of Predictive Models for Inhibitors of 5-alpha Reductase 2 Based on the Integration of Bioactivity and Molecular Descriptors Data

  2014cites this paper
• Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study

  2014cites this paper
• Is men's health just a single letter?

  2014cites this paper
• Influence of sex steroids on inflammation and bone metabolism.

  2014cites this paper
• Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review.

  2013cites this paper
• Pathophysiology—Prostate Cancer

  2013cites this paper
• Clinical biochemistry of dihydrotestosterone

  2013cites this paper
• Effect of finasteride on lipid profile in individuals with androgenetic alopecia

  2013cites this paper
• The role of 5α-reductase inhibition in men receiving testosterone replacement therapy.

  2012cites this paper
• Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

  2012cites this paper
• Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy.

  2012cites this paper
• The relationships between sex hormones and sexual function in middle-aged and older European men.

  2011cites this paper
• Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.

  2011cites this paper
• The role of non-aromatizable testosterone metabolite in metabolic pathways.

  2011cites this paper
• Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

  2011cites this paper
• Risk of fractures associated with treatment for benign prostate hyperplasia in men

  2011cites this paper
• Androgenic Alopecia

  2010cites this paper
• THE ROLE AND EFFECT OF FINASTERIDE ON THE SPERMATOGENESIS, PROSTATE GLAND AND EPIDIDYM OF MATURE NMRI MOUSE IN IN VIVO AND IN VITRO CONDITIONS

  2010cites this paper
• Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride.

  2010cites this paper
• Effect of the dual 5α‐reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia

  2010cites this paper
• Methods to quantify sex steroid hormones in bone: applications to the study of androgen ablation and administration.

  2010cites this paper
• Testosterone Therapy for Osteoporosis in Men

  2010cites this paper
• Osteoporosi maschile: il ruolo degli estrogeni

  2009cites this paper
• Finasteride in the treatment of patients with benign prostatic hyperplasia: a review

  2009cites this paper
• Measurement of benign prostatic hyperplasia treatment effects on male sexual function

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• Male osteoporosis and androgenic therapy: from testosterone to SARMs.

  2009cites this paper
• Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats.

  2008cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper